WASHINGTON, DC and DENVER, JANUARY 6, 2021 – The Global Liver Institute (GLI), the only patient-led liver health nonprofit operating internationally, in partnership with TriSalus Life...
Fatty liver disease (FLD) and nonalcoholic steatohepatitis (NASH) are increasing in prevalence worldwide, creating a major global public health crisis. To adequately educate patients, practitioners,...
POLICY PERSPECTIVE In the past, efforts in liver advocacy were siloed by individual liver disease lessening their impact and limiting their effectiveness at shaping national health policy. In 2021...
On February 4, 2022 10 AM ET, Global Liver Institute led an Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD) on Primary Biliary Cholangitis (PBC). This online event is open to the...
Donna R. Cryer, JD, President and CEO, Honored with Awards from the American Association for the Study of Liver Diseases (AASLD) and Global Genes for leadership in connecting, empowering, inspiring...
POLICY PERSPECTIVE The liver advocacy community — with the GLI Liver Action Network leading the way — has elevated patient voices through a variety of initiatives throughout September and October....
Fatty liver disease (FLD) and nonalcoholic steatohepatitis (NASH) are increasing in prevalence worldwide, creating a major global public health crisis. To adequately educate patients, practitioners,...
Dear Colleague: October is Liver Cancer Awareness Month. This represents an opportunity to draw attention to the global burden of liver cancer and to highlight the various public health...
On November 4th at 10 AM ET, Global Liver Institute led an Externally Led Patient-Focused Drug Development Meeting on NASH for the FDA. This online event is open to the public with registration...
(Washington, DC, Friday, October 22, 2021)—Global Liver Institute (GLI) CEO and President, Donna R. Cryer, JD, yesterday applauded the actions of U.S. Representative Nydia Velázquez...
Recent News
GLI Supports the Bipartisan Reintroduction of the Treat and Reduce Obesity Act(Washington, D.C., July 8, 2025) – Global Liver Institute (GLI) applauds the reintroduction of the bipartisan Treat and Reduce Obesity Act (TROA) in the U.S. House of Representatives last...
Treatment Strategies and Advancements in TestingGlobal Liver Institute brings you key updates on emerging treatment strategies and advocacy efforts from global leaders like the World Hepatitis Alliance. In this issue, we offer new resources, a short quiz to see if...
Global Research and Patient Priorities Emphasizing the Importance of Using Patient-Reported Data at the DIA 2025 Conference, Washington, D.C. Kristin Hatcher, Director of GLI’s Pediatric and Rare Liver Disease Program, joined U.S. and global...
Culturally Relevant Tools to Increase Hepatitis B Screening in Asian American CommunitiesInfection with hepatitis B poses a serious risk to the health of many Americans – especially in certain groups with high risk, including Asian Americans and Asian-American...
Global Liver Institute Leads Efforts in Urging FDA to Recognize Patient-Defined Progress in Drug Development(Washington, D.C. June 24, 2025) – At the Global Liver Institute, we believe that it all starts with a patient because only they define what progress means to...
